Genentech’s Vabysmo Boasts Increasingly Favorable Perceptions Among Ophthalmologists for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema, According to Spherix Global Insights
Despite Vabysmo’s positive first impressions, the race is about to heat up with the widely anticipated FDA approval of Regeneron’s 8mg aflibercept potentially around the corner. EXTON, Pa., June 7, 2023 /PRNewswire/ — Genentech’s Vabysmo got an 18-month head start over Regeneron’s high dose Eylea (8mg aflibercept), but that lead time may be coming to … Read more